XGN · Exagen Inc. · Executive Compensation
Market Cap
$176.12M
Shares
24.23M
Volume · Oct 23
222.8K
Avg daily vol (3M)
358.01K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| John Aballi | President, Chief Executive Officer, Director and former Interim Chief Financial Officer | $1,400,868 |
| Jeffrey Black | Chief Financial Officer and Corporate Secretary Amounts represent the aggregate grant date fair value of restricted stock unit awards granted to the NEO in the applicable year, as computed in accordance with ASC Topic 718, Compensation-Stock Compensation, rather than the amounts paid to or realized by the NEO. For a discussion of valuation assumptions used in the calculations, see Note 2 and Note 9 to our audited financial statements in our 2025 Annual Report. Amounts reflect the aggregate grant date fair value of stock options granted in 2025 as computed in accordance with ASC Topic 718, Compensation-Stock Compensation. These amounts do not reflect the actual economic value that will be realized by the NEO upon the vesting of the stock options, the exercise of the stock options, or the sale of the common stock underlying such stock options. The assumptions that we used to calculate these amounts are discussed in Note 2 and Note 9 to our audited financial statements in our 2025 Annual Report. Amounts for 2025 and 2024 represent the non-discretionary portion of cash bonuses paid in March 2026 and March 2025 with respect to corporate performance in 2025 and 2024, respectively, under the bonus plan. For additional information, see "Cash Bonuses" below. Amounts for 2025 and 2024 represent employer matching contributions under our 401(k) plan on behalf of each NEO. Mr. Aballi was appointed as Interim Chief Financial Officer in July 2024 and resigned as Interim Chief Financial Officer in September 2024. Mr. Aballi did not receive additional compensation for the time he served as Interim Chief Financial Officer. Mr. Black was appointed as the Company’s Chief Financial Officer and Corporate Secretary in September 2024. | $746,190 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| John Aballi | President, Chief Executive Officer, and Director | $1,184,500 |
| Jeffrey Black | Chief Financial Officer and Corporate Secretary | $1,021,036 |
| Kamal Adawi | Former Chief Financial Officer and Corporate Secretary | $790,290 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Mark Hazeltine | former Chief Business Officer Amounts represent the aggregate grant date fair value of restricted stock unit awards granted to the named executive officer in the applicable year, as computed in accordance with ASC Topic 718, Compensation-Stock Compensation, rather than the amounts paid to or realized by the named executive officer. For a discussion of valuation assumptions used in the calculations, see Note 2 and Note 9 to our audited financial statements in our 2023 Annual Report. Amounts for 2023 represent the non-discretionary portion of cash bonuses paid in March 2024 with respect to 2023 corporate performance under the bonus plan. For additional information, see "Cash Bonuses" below. Amounts for 2023 represent employer matching contributions under our 401(k) plan on behalf of each named executive officer, and severance payments, paid time off payouts and Consolidated Omnibus Budget Reconciliation Act (COBRA) payments to Mr. Hazeltine in the amounts of $421,438, $23,599 and $15,140, respectively. | $1,053,994 |
| John Aballi | President, Chief Executive Officer, and Director | $931,950 |
| Kamal Adawi | Former Chief Financial Officer and Corporate Secretary | $915,087 |
| Jeffrey Black | Chief Financial Officer and Corporate Secretary | — |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Fortunato Ron Rocca | former President and Chief Executive Officer | $1,542,043 |
| Kamal Adawi | Chief Financial Officer and Corporate Secretary | $1,040,175 |
| Mark Hazeltine | former Chief Business Officer Amounts represent the aggregate grant date fair value of restricted stock unit awards granted to the named executive officer in the applicable year, as computed in accordance with ASC Topic 718, Compensation-Stock Compensation, rather than the amounts paid to or realized by the named executive officer. For a discussion of valuation assumptions used in the calculations, see Note 2 and Note 9 to our audited financial statements in our 2023 Annual Report. Amounts for 2023 represent the non-discretionary portion of cash bonuses paid in March 2024 with respect to 2023 corporate performance under the bonus plan. For additional information, see "Cash Bonuses" below. Amounts for 2023 represent employer matching contributions under our 401(k) plan on behalf of each named executive officer, and severance payments, paid time off payouts and Consolidated Omnibus Budget Reconciliation Act (COBRA) payments to Mr. Hazeltine in the amounts of $421,438, $23,599 and $15,140, respectively. | $1,040,175 |
| Debra Zack | M.D., Ph.D. former Chief Medical Officer | $1,025,956 |
| John Aballi | President and Chief Executive Officer | $983,886 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Fortunato Ron Rocca | former President and Chief Executive Officer | $2,439,628 |
| Debra Zack | M.D., Ph.D. former Chief Medical Officer | $1,430,559 |
| Kamal Adawi | Chief Financial Officer and Corporate Secretary | $1,413,557 |
| Mark Hazeltine | Chief Business Officer | $1,397,753 |
| John Aballi | President and Chief Executive Officer | — |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Fortunato Ron Rocca | President and Chief Executive Officer | $2,817,685 |
| Kamal Adawi | Chief Financial Officer and Corporate Secretary | $1,210,537 |
| Debra Zack | M.D., Ph.D. Chief Medical Officer Amounts for 2021 represent the full grant date fair value of restricted stock unit awards granted to the named executive officer in the applicable year, as computed in accordance with ASC Topic 718, Compensation-Stock Compensation, rather than the amounts paid to or realized by the named executive officer. For a discussion of valuation assumptions used in the calculations, see Note 2 and Note 8 to our audited financial statements in our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on March 22, 2022. Amounts for 2021 reflect the aggregate grant date fair value of stock options granted in 2021. Each option grant has been computed in accordance with ASC Topic 718, Compensation-Stock Compensation. These amounts do not reflect the actual economic value that will be realized by the named executive officer upon the vesting of the stock options, the exercise of the stock options, or the sale of the common stock underlying such stock options. The assumptions that we used to calculate these amounts are discussed in Note 2 and Note 8 to our audited financial statements in our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on March 22, 2022. Amounts for 2021 represent the non-discretionary portion of cash bonuses paid in January 2022 with respect to 2021 corporate performance under the bonus plan. For additional information, see -"Bonus", below. Represents employer matching contributions under our 401(k) plan on behalf of each named executive officer. | $1,122,282 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Fortunato Ron Rocca | President and Chief Executive Officer | $1,627,725 |
| Kamal Adawi | Chief Financial Officer and Corporate Secretary | $524,866 |
| Thierry Dervieux | Chief Scientific Officer | $466,966 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Fortunato Ron Rocca | President and Chief Executive Officer | $567,219 |
| Thierry Dervieux | Chief Scientific Officer | $365,611 |
| Kamal Adawi | Chief Financial Officer and Corporate Secretary | $354,287 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Ana Hooker | member of the Board | Resigned | 2026-04-23 |
| Charles S. McKhann | Class III director | Appointed | 2025-07-17 |
| John Aballi | Interim Chief Financial Officer | Appointed | 2024-08-02 |
| Jeffrey Black | Chief Financial Officer and principal financial officer for SEC reporting purposes | Appointed | 2024-08-02 |
| Scott D. Kahn, Ph.D. | Class I director | Appointed | 2024-04-26 |
| Wendy Johnson | member of the Board | Resigned | 2024-04-26 |
| Ebetual Pallares, Ph.D. | member of the Board | Resigned | 2024-04-26 |
| Brian Birk | member of the Board | Resigned | 2024-04-26 |
| Mark Hazeltine | Chief Business Officer | Resigned | 2023-12-11 |
| Paul Kim | Class II director | Appointed | 2023-07-24 |
| Mark Hazeltine | Chief Business Officer | Appointed | 2022-12-05 |
| Debra Zack, M.D., Ph.D. | Chief Medical Officer | Terminated | 2022-12-05 |
| Fortunato Ron Rocca | Board of Directors of Exagen Inc. | Resigned | 2022-10-20 |
| John Aballi | member of the Board | Appointed | 2022-10-20 |
| Fortunato Ron Rocca | President and Chief Executive Officer | Resigned | 2022-10-20 |
| Fortunato Ron Rocca | member of the Board of Directors | Resigned | 2022-10-20 |
| John Aballi | member of the board of directors | Appointed | 2022-10-20 |
| John Aballi | President and Chief Executive Officer | Appointed | 2022-10-20 |
Leadership
- John Aballi CEO, CFO, Board Member
- Tina S. Nova Chairman
- Jeffrey Black CFO
- Mark Hazeltine COO
- Bruce C. Robertson Board Member
- Charles S. McKhann Board Member
- Frank Stokes Board Member
- Paul Kim Board Member
- Scott D. Kahn Board Member
- Scott D. Kahn, Ph.D. Board Member